|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Drug Interactions]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ====Drug Interactions====
| |
| | |
| Ticagrelor is predominantly metabolized by [[CYP3A4]] and to a lesser extent by [[CYP3A5]]. Ticagrelor is also a p-glycoprotein (P-gp) substrate.
| |
| | |
| ====CYP3A inhibitors====
| |
| | |
| Avoid use of strong inhibitors of [[CYP3A]] (e.g., [[ketoconazole]], [[itraconazole]], [[voriconazole]], [[clarithromycin]], [[nefazodone]], [[ritonavir]], [[saquinavir]], [[nelfinavir]], [[indinavir]], [[atazanavir]] and [[telithromycin]]). See [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor clinical pharmacology|Clinical pharmacology]].
| |
| | |
| ====CYP3A inducers====
| |
| | |
| Avoid use with potent inducers of [[CYP3A]] (e.g., [[rifampin]], [[dexamethasone]], [[phenytoin]], [[carbamazepine]] and [[phenobarbital]]). See [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor clinical pharmacology|Clinical pharmacology]].
| |
| | |
| ====Aspirin====
| |
| | |
| Use of BRILINTA with [[aspirin]] maintenance doses above 100 mg reduced the effectiveness of BRILINTA. [See [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor clinical pharmacology|Clinical pharmacology]]].
| |
| ====Effects of BRILINTA on other drugs====
| |
| | |
| Ticagrelor is an inhibitor of CYP3A4/5 and the [[P-glycoprotein]] transporter.
| |
| | |
| '''* Simvastatin, lovastatin'''
| |
| | |
| BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by [[CYP3A4]]. Avoid [[simvastatin]] and [[lovastatin]] doses greater than 40 mg. See [[Ticagrelor clinical pharmacology|Clinical pharmacology]].
| |
| | |
| '''* Digoxin'''
| |
| | |
| Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy [see Clinical Pharmacology (12.3)].
| |
| | |
| '''* Other Concomitant Therapy'''
| |
| | |
| BRILINTA can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.<ref>{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 12 March 2014 }}</ref>
| |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |